Regulatory approvals for antibody-drug conjugates (ADCs) have accelerated rapidly over recent years due to advancements in linker technology and targeted payloads. As of recent regulatory tracking and pharmaceutical updates, more than 15 to 20 distinct ADC therapies have secured formal FDA approvals for various oncology indications, covering numerous solid tumors such as breast, lung, and bladder cancers, as well as diverse hematological malignancies like lymphomas and leukemias.